Tally counts 32 FDA warning letters on GLP-1s and peptides since December 2024

A register maintained by an independent health site counts 32 FDA warning letters touching GLP-1 medicines and research peptides since December 2024, with the count taken on September 12, 2026 ^[1]. The letters are not one campaign but three, split by who received them: 17 went to telehealth and compounding businesses, 12 went to research-peptide sellers, and 3 went to Eli Lilly and Novo Nordisk, the companies that make the approved drugs themselves ^[1].

The first letters appeared on December 10, 2024, to two research-peptide sellers, and the most recent tracked batch is dated August 24, 2026 ^[1]. The largest single action came on June 8, 2026, when 13 letters went out in one day to telehealth and compounding-adjacent businesses, including NativeMed, HydraMed, Harper Meds, AM RX, Altru Telehealth, Maximus, altRx, Mint Med, Ezra, DrMedHealth, D&H Medical Services, Amie and Momentum Health ^[1]. Thirteen letters landing on one date, to companies that compete with each other, points to a coordinated action rather than routine, scattered inspections ^[1].

The manufacturers were not left out. Eli Lilly and Novo Nordisk each received a letter on September 9, 2025, and Novo Nordisk received a second one on March 5, 2026 ^[1]. A warning letter is a finding about conduct — most often how a product was promoted — and the agency has sent them to the largest companies in the category as well as to small shops, which the tracker's authors say is worth keeping in mind when reading the other 29 ^[1].

The five letters dated August 24, 2026, and posted by the FDA on September 1, are described as legally distinct from the rest. They went to five online sellers — Peptide Partners LLC, Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC and TXP Innovations LLC (doing business as Tex Peptides) — over products including injectable semaglutide, tirzepatide, retatrutide, tesamorelin, elamipretide (SS-31) and bremelanotide (PT-141) sold under "research use only" labels ^[2]. Rather than alleging misbranding, these letters classify the products as unapproved new drugs in violation of sections 301(d) and 505(a) of the Food, Drug and Cosmetic Act, and reject the research-use disclaimer outright ^[1][2].

Why it matters for patients

The count itself does not say anything about whether any specific product is unsafe. The tracker's authors are explicit that the great majority of the 32 letters do not describe testing, contamination, potency failure, or patient harm — those questions are separate from what a warning letter documents ^[1]. What the letters do show is where the agency's attention has gone: at telehealth and compounding operations selling GLP-1-adjacent products, at online peptide sellers using research-only labels, and even at the manufacturers of Ozempic, Wegovy, Mounjaro and Zepbound over promotional conduct ^[1].

For someone weighing a compounded or peptide product against an FDA-approved one, the August wave is a signal that the agency is now willing to argue some products should not be sold at all, not just that they were marketed in a misleading way ^[1][2]. That is a different and more consequential legal claim than the misbranding findings that made up most of the earlier letters ^[1].

What happens next

The tracker notes its counts will go out of date as new letters are issued, and recommends citing the date alongside any number pulled from it ^[1]. Separately, a related timeline notes that a federal appeals court upheld the FDA's removal of semaglutide and tirzepatide from the drug shortage list on August 27, 2026, which ended bulk compounding of those molecules for general use while leaving patient-specific compounding for documented individual need in place ^[2].